Learn More About Embosphere® Microspheres

Features & Benefits

Regulatory Information


Embosphere Microspheres are indicated for use in embolization of arteriovenous malformations, hypervascular tumors, symptomatic uterine fibroids, and the prostate arteries for relief of symptoms related to Benign Prostatic Hyperplasia (BPH).

European Union

Embosphere Microspheres are indicated for use in hemostatic embolization and in embolization of arteriovenous malformations, hypervascular tumors, including uterine fibroids and meningiomas, and the prostate arteries for relief of symptoms related to Benign Prostatic Hyperplasia (BPH).

Embosphere Microspheres are indicated for use in the embolization of:

  • Hypervascular tumors, including symptomatic uterine fibroids
  • Prostatic arteries for symptomatic Benign Prostatic Hyperplasia (BPH)
  • Arteriovenous malformations
  • Blood vessels to occlude blood flow to control bleeding/hemorrhaging in the peripheral vasculature

1 Data as of January 2016



Embosphere Microspheres exhibit a consistent cross-sectional diameter for targeted delivery. Their round shape matches the vessel lumen to help ensure occlusion.

Durable Occlusion

Embosphere Microspheres are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.

Compressible and Resilient Material

Elastic properties allow temporary compression of up to 33%, facilitating smooth microcatheter passage. Resilient material returns to stated diameter after delivery, contributing to durable and targeted results.

Non-Aggregating Properties

The hydrophilic surface and spherical shape of Embosphere Microspheres prevent aggregation in the catheter lumen and vasculature.

Predictable Distribution

Because they are non-aggregating, Embosphere Microspheres distribute predictably after embolization.

Highly Targeted Delivery

Embosphere Microspheres are available in six size ranges to allow physicians to target the microvasculature of the tumor and shut down the feeder network while maintaining patency of the major artery feeding the organ.

The Clinically Proven Round Embolic

“Given the known risk of recurrence in patients with persistent tumor enhancement after UAE, it is concluded that tris-acryl gelatin microspheres should be the preferred agent for UAE at this time.”

Siskin GP, et al. Leiomyoma Infarction after Uterine Artery Embolization:
A Prospective Randomized Study Comparing Tris-acryl Gelatin Microspheres versus Polyvinyl Alcohol Microspheres. J Vasc Interv Radiol 2008; 19: 58-65.

“The primary embolic agent used was calibrated microspheres in 73% of cases
(either Embosphere or Embosphere Gold, Biosphere Medical, Rockland, MA)…”

Siskin GP, et al. Leiomyoma Infarction after Uterine Artery Embolization:
Worthington-Kirsch R, et al. The Fibroid Registry for Outcomes Data (FIBROID) for Uterine Embolization – Short Term Outcomes. Obstet & Gynecol 2005; 106: 52-9.

”[Patients] treated with TAGM were significantly more likely to have complete
infarction of all leiomyomas…The use of spherical PVA particles in the manner
described herein results in an unacceptably high rate of failed tumor infarction
in UAE.“

Spies JB, et al. Spherical Polyvinyl Alcohol Versus Trisacryl Gelatin Microspheres for Uterine Artery Embolization for Leiomyomas: Results of a Limited Randomized Comparative Study. J Vasc Interv Radiol 2005;16:1431-7.

“Over the long term, UFE using TAGM is effective and safe, with high levels
of durable symptom control, improved health-related quality of life and
patient satisfaction.”

Spies JB, et al. Long-Term Outcome from Uterine Fibroid Embolization
Using Tris-Acryl Gelatin Microspheres. J Vasc Interv Radiol 2007; 18: 203-7

If you think you are a candidate for Uterine Fibroid Embolisation (UFE), please refer to ask4ufe.com for more information.

Ordering Information

View Fullscreen

Catalog NumberExpanded Family NameSize RangeDelivery SystemDelivery System SizeColorCarrier SolutionVolumeHCPCS Code
S020GHEmbosphere® Microspheres50-100 µmSyringe20 mLGrayNormal Saline2.0 mL
S1010GHEmbosphere® Microspheres900-1200 µmSyringe20 mLPurpleNormal Saline1.0 mL
S1020GHEmbosphere® Microspheres900-1200 µmSyringe20 mLPurpleNormal Saline2.0 mL
S120GHEmbosphere® Microspheres40-120 µmSyringe20 mLOrangeNormal Saline2.0 mL
S210GHEmbosphere® Microspheres100-300 µmSyringe20 mLYellowNormal Saline1.0 mL
S220GHEmbosphere® Microspheres100-300 µmSyringe20 mLYellowNormal Saline2.0 mL
S410GHEmbosphere® Microspheres300-500 µmSyringe20 mLBlueNormal Saline1.0 mL
S420GHEmbosphere® Microspheres300-500 µmSyringe20 mLBlueNormal Saline2.0 mL
S610GHEmbosphere® Microspheres500-700 µmSyringe20 mLRedNormal Saline1.0 mL
S620GHEmbosphere® Microspheres500-700 µmSyringe20 mLRedNormal Saline2.0 mL
S810GHEmbosphere® Microspheres700-900 µmSyringe20 mLGreenNormal Saline1.0 mL
S820GHEmbosphere® Microspheres700-900 µmSyringe20 mLGreenNormal Saline2.0 mL
V1010GHEmbosphere® Microspheres900-1200 µmVial5 mLPurpleNormal Saline1.0 mLNo Applicable Code
V1020GHEmbosphere® Microspheres900-1200 µmVial5 mLPurpleNormal Saline2.0 mLNo Applicable Code
V110GHEmbosphere® Microspheres40-120 µmVial5 mLOrangeNormal Saline1.0 mLNo Applicable Code
V120GHEmbosphere® Microspheres40-120 µmVial5 mLOrangeNormal Saline2.0 mLNo Applicable Code
V210GHEmbosphere® Microspheres100-300 µmVial5 mLYellowNormal Saline1.0 mLNo Applicable Code
V220GHEmbosphere® Microspheres100-300 µmVial5 mLYellowNormal Saline2.0 mLNo Applicable Code
V410GHEmbosphere® Microspheres300-500 µmVial5 mLBlueNormal Saline1.0 mLNo Applicable Code
V420GHEmbosphere® Microspheres300-500 µmVial5 mLBlueNormal Saline2.0 mLNo Applicable Code
V610GHEmbosphere® Microspheres500-700 µmVial5 mLRedNormal Saline1.0 mLNo Applicable Code
V620GHEmbosphere® Microspheres500-700 µmVial5 mLRedNormal Saline2.0 mLNo Applicable Code
V810GHEmbosphere® Microspheres700-900 µmVial5 mLGreenNormal Saline1.0 mLNo Applicable Code
V820GHEmbosphere® Microspheres700-900 µmVial5 mLGreenNormal Saline2.0 mLNo Applicable Code